Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

AlloSure Lung Assessment and Metagenomics Outcomes Study

NCT05050955 · View on ClinicalTrials.gov ↗

Study Summary

ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) for surveillance post-transplant. This study aims to evaluate the diagnostic performance characteristics of AlloSure Lung (dd-cfDNA) to detect a spectrum of rejection (ACR, AMR) and allograft infection (Bacterial, Viral, Fungal, Mycobacterial, Parasitic).

Study Locations (20)

New York

  • NYU Langone Health — New York
  • Columbia University Medical Center — New York
  • Montefiore Medical Center — The Bronx

California

  • Cedars Sinai Medical Center — Los Angeles
  • University of California (UCSF) School of Medicine — San Francisco

Pennsylvania

  • University of Pennsylvania — Philadelphia
  • Temple University — Philadelphia

Alabama

  • University of Alabama (UAB) — Birmingham

Arizona

  • St. Joseph's Hospital & Medical Center — Phoenix

Colorado

  • University of CO Anschutz Medical Campus — Aurora

Florida

  • AdventHealth Orlando — Orlando

Illinois

  • Loyola University Medical School — Maywood

Trial Details

FieldValue
Enrollment Target 550 participants
Start Date 2021-10-29
Est. Completion 2028-12-31

Sponsor

CareDx

5 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05050955

The ClinicalTrials.gov registry entry for NCT05050955 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CareDx, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Lung Transplant; Complications appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05050955 reports 20 study locations spanning 16 distinct geographic areas — top geographies include New York, California, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05050955 about?

NCT05050955 is a clinical study titled "AlloSure Lung Assessment and Metagenomics Outcomes Study". ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) for surveillance post-transplant. This study aims to evaluate the diagnostic performance characteristics of AlloSure Lung (dd-cfDNA) to detect a spectrum of reject...

What is the current status of trial NCT05050955?

This trial is currently active not recruiting. The enrollment target is 550 participants. The study started on 2021-10-29. Estimated completion is 2028-12-31.

What conditions does trial NCT05050955 study?

This clinical trial studies the following conditions: Lung Transplant; Complications, Lung Transplant Failure and Rejection, Lung Transplant Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT05050955?

This trial is sponsored by CareDx, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05050955 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial